Immediate and long-term @entity137 of adjuvant chemotherapy regimens containing XXXX in trials at M.D. Anderson Hospital and @entity5 Institute.

@entity1 @entity632 @entity1665 @entity137 @entity390 @entity0 @entity712 @entity5 @entity391 @entity786 @entity1866 @entity1370 @entity2670 @entity2588 @entity1487
Seven hundred and ninety-six consecutive @entity1 with operable primary @entity0 treated with @entity632 -containing postoperative adjuvant chemotherapy between 1974 and 1982 were evaluated for assessment of the acute and long-term @entity137 of the program. Most @entity1 experienced @entity390 , @entity391 , and @entity1665 , side effects that were totally reversible. @entity632 skin infiltration was observed in 6% of the @entity1 . Hematologic @entity137 was moderate, and only 26% of the @entity1 had a granulocyte nadir of less than 1000 cells/ml. Febrile or infectious complications occurred in 6% of @entity1 , of which 3% required hospitalization for observation and antibiotic treatment. No long-term hematologic changes were observed. @entity2588 was reported by 80% of premenopausal @entity1 . However, none of the @entity1 under 30 years of age had @entity1866 , whereas 96% of those 40-49 years of age developed @entity2588 . @entity2588 was permanent for most @entity1 over 40, but for 50% of @entity1 under 40 years of age, it was reversible. Endocrinologic studies showed that @entity2588 was a result of @entity2670 . The incidence of second @entity5 was lower (1.3%) in the group treated with @entity1487 , @entity632 , and @entity786 than in the historical control group (4.8%). @entity1370 data was evaluated in 460 @entity1 . When up to a cumulative dose of 300 mg/m2 was given, 1% of the @entity1 developed @entity712 . In 4 of these 5, adequate control was achieved with medical treatment; 1 @entity1 died as a consequence of @entity1370 .
